PMDA drug package insert
ナリピタン 当帰芍薬散錠
PMDA OTC drug · 小林製薬（株） · package insert Aug 31, 2023
Key facts
| Brand names | ナリピタン 当帰芍薬散錠 |
|---|---|
| Companies | 製造販売元／小林製薬（株） |
| Product type | OTC drug |
| OTC risk class | 第２類医薬品 |
| OTC dosage form | 錠剤 |
| OTC effect category | 当帰芍薬散 |
| Package insert date | Aug 31, 2023 |
| PMDA document key | 270172_K2204000011 |
| PMDA company code | 270172 |
At a glance
- 1–9 Package insert revisions
- None Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: